R&D News | pharmaphorum

News

AZ drops two trials aimed at expanding Lokelma’s label

AstraZeneca has decided to abandon two phase 3 trials of its drug to reduce high levels of potassium in the blood (hyperkalaemia) – Lokelma – in patients with kidney disea

News

Cybin preps for ph3 as psychedelic clears depression trial

Cybin has unveiled phase 2 results with its psychedelic medicine for major depressive disorder, which it says support moving the drug into a phase 3 programme.

News

AbbVie agrees $10.1bn deal to buy ImmunoGen

AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovar

News

Could high HDL-cholesterol raise dementia risk?

A new study has added to data suggesting that HDL cholesterol (HDL-c) – sometimes called ‘good’ cholesterol, as it can help protect against heart disease – may be a risk f

News

Astellas builds case for menopause drug fezolinetant

New data for Astellas Pharma’s non-hormonal menopause therapy fezolinetant has shown it remains effective to 24 weeks, consolidating the evidence of the drug as it starts

News

UK Biobank releases largest-ever genome sequencing dataset

After five years of painstaking lab work, more than 350,000 hours of genome sequencing and £200 million ($253 million) in investment, UK Biobank has completed and released the full se

AZ drops two trials aimed at expanding Lokelma’s label

Cybin preps for ph3 as psychedelic clears depression trial

AbbVie agrees $10.1bn deal to buy ImmunoGen

Could high HDL-cholesterol raise dementia risk?

Astellas builds case for menopause drug fezolinetant

UK Biobank releases largest-ever genome sequencing dataset

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks